OWP
RNAM

Old Well Partners’s Avidity Biosciences RNAM Stock Holding History

Old Well Partners’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-8,548
Closed -$203K – 42
2021
Q4 		$203K Hold
8,548
– – 0.13% 29
2021
Q3 		$211K Buy
+8,548
New +$186K 0.11% 28

Other funds holding RNAM

AWA
Aaron Wealth Advisors Chicago, Illinois $1.97B AUM 36.91% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Old Well Partners's RNAM Position: Q1 2022 in Review

Old Well Partners sold out of Avidity Biosciences (RNAM) in Q1 2022, closing a stake of 8,548 shares — an estimated $203K sold.

Old Well Partners first reported a position in RNAM in Q3 2021 and held it in 2 quarters. The position peaked at $211K in Q3 2021. 103 funds tracked by Wall St. Rank hold RNAM as of Q1 2022.

  • Old Well Partners reported no remaining Avidity Biosciences position as of Q1 2022 after selling out during the quarter.
  • Old Well Partners sold 8,548 Avidity Biosciences shares in Q1 2022, an estimated $203K.
  • Old Well Partners first reported a position in Avidity Biosciences in Q3 2021 and held it in 2 quarters.
  • Old Well Partners's Avidity Biosciences position peaked at $211K in Q3 2021.
  • 103 funds tracked by Wall St. Rank held Avidity Biosciences as of Q1 2022.

Based on Old Well Partners's 13F filing for Q1 2022, filed 16 May 2022.